The CCyR rate was 53% and the major molecular response was 47%. Additionally

After a median 14 months of treatment, 1. 9% of patients had progressed to AP blast phase with dasatinib compared with 3. 5% with imatinib. No patient in whom a MMR was achieved progressed to AP24534 Ponatinib AP BP, In the ENESTnd trial, the primary endpoint was the rate of MMR at 12 months, and both nilotinib arms had significantly higher rates compared with the imatinib arm, Rates of CCyR achieved by 12 months were also significantly higher for nilotinib vs imatinib, and CCyR and MMR occurred faster in the niloti nib arms. After a median 14 months of treatment, fewer nilotinib treated patients had progressed to AP BP phase compared with imatinib treated patients, Similar DASISION, no patient who had a MMR had progression to AP BP, Five year follow up is planned in both trials.<br><br> Because available data suggest that both dasatinib and nilotinib have broadly similar efficacy in terms of their superiority over imatinib, it is likely that safety and tolerability considerations for these agents will become increasingly important when selecting first line treatment for CML. The importance of adherence Across various chronic diseases AT-406 分子量 mw requiring long term treatment, poor adherence is associated with worse out comes, Similarly, recent studies have shown that lack of adherence to imatinib treatment results in signif icantly lower response rates in patients with CP CML. In a prospective observational study, adherence to imatinib treatment was analyzed in 169 patients with CML during a 90 day period and corre lated with overall responses to treatment.<br><br> Only 14% of patients were found to be perfectly adherent based on pill counts, with 71% of patients taking less AKT 阻害剤 imatinib than prescribed and 15% taking more imatinib than prescribed. Importantly, worse adherence was associated with worse treatment responses; patients who had a suboptimal response to imatinib had significant higher mean percentage of ima tinib not taken than those with an optimal response, Similarly, patients who failed to achieve a CCyR on imatinib had a higher mean percen tage of pills not taken than patients who achieved a CCyR, In another prospec tive observational study performed at a single institu tion, 87 patients with CP CML who had achieved a CCyR on imatinib were monitored for adherence for 90 days using a microelectronic monitoring device. The adherence rate was 90% in 26% and 80% in 14%.<br><br> There was a strong correlation between adherence to imatinib and probabilities of MMR and CMR; patients with 90% adherence had a lower 6 year rate of MMR than patients with 90% adherence, no patient with 90% adherence achieved a CMR, and no patient with 80% adherence achieved a MMR. Significantly worse adherence rates were found in patients with various adverse events, including asthenia, nausea, muscle cramps, and bone or joint pains, and also in patients who took imatinib indepen dently of meals.